
    
      To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol
      0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study
      structure is a parallel design. The patients will receive treatment for 12 weeks.
    
  